First,
we carried out and validated a monocyte-to-macrophage polarization protocol to generate
some macrophage subtypes (M0, M1 and M2). M0 were generated through exposure of
THP1 monocytes to different concentrations (25 or 100 ng/ml) of phorbol
12-myristate-13 acetate (PMA) during 24h. Then, M0 were differentiated in M1
with lipopolysaccharides (LPS) and IFN-γ or in M2 with IL-4 and IL-13 human
interleukins. The different phenotypes were confirmed by the identification of
some characteristic markers by immunofluorescence (CD14, CD36, CD68, CD86,
CD206, NRF2, NF-κB), RTqPCR (CD68, CD80, SOCS1, SOCS3, IL-12, PD-L1, CCL2,
CD206, KGA, SLC1A5, NOX2, SOD2, NRF2) and FACS (CD14, CD68, CD80, CD163, CD206).
Moreover, we evaluate the stability of the different phenotypes over 72h. We
would like to switch M2 phenotype to M1 by targeting metabolism using CB839 and
ROS by using PRIMA-1MET. We will also irradiate M2 with x-ray and
expose them with Fe2O3 nanoparticles.